CoronaryAtlas logo
CoronaryAtlas
Cystatin C
Pathway / Off-pathway / systemic markers

Cystatin C

CST3protein

Cystatin C reflects glomerular filtration and renal function; elevated levels indicate cardiorenal risk and mortality in acute coronary syndrome.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencehigh
RationaleRenal function and cardiorenal stress marker; prognostic indicator independent of atherothrombotic cascade.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000101439

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
67
A — assay feasibility
68
E — evidence strength
62
T1DI (composite)
16
Specificity differential (R−C)-24
Direct evidence: higher in non-Type I (D=-2)
Type 1 MI: 1.07 mg/L vs Type 2 MI: 1.24 mg/L (significantly higher in T2, p<0.05 after adjustment)
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationmag 2
2tachyarrhythmian/a
2hypoxemia / respiratory failuremag 2
2hypertensive emergencyn/a
2high-demand / peri-operative stressmag 2
3sudden cardiac deathmag 2
4aPCI-related periproceduralmag 2
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedmag 2
Coverage: 8/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 21 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top)
Method / principle
Immunoturbidimetric/nephelometric
Reagent / substrate
Anti-cystatin C antibody-latex
Platform
Automated analyzer
Turnaround · availability
Routine · Widely available

Human genetic evidence

0.016
Open Targets association (STEMI)

Literature evidence(17)